参考文献
1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Pancreatic Adenocarcinoma Version 1.2019 -November 8, 2018.
2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed., 2017).
3.Worni M, Guller U, White RR, et al.Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008.Pancreas 2013, 42: 1157-1163.
4.Antwi SO, Eckert EC, Sabaque CV, et al.Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer.Cancer Causes Control 2015, 26: 1583-1591.
5.Maisonneuve P, Amar S, Lowenfels AB.Periodontal disease, edentulism, and pancreatic cancer: a metaanalysis.Ann Oncol 2017, 28: 985-995.
6.Oettle H, Neuhaus P, Hochhaus A, et al.Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.JAMA 2013, 310: 1473-1481.
7.Greenhalf W, Ghaneh P, Neoptolemos JP, et al.Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.J Natl Cancer Inst 2014, 106: djt347.
8.Zhu Y, Qi M, Lao L, et al.Human equilibrative nucleoside transporter1predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.Genet Test Mol Biomarkers 2014.
9.Chiorean EG, Von Hoff DD, Reni M, et al.CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial(MPACT)of weekly nabpaclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.Ann Oncol 2016, 27: 654-660.
10.Goldstein D, El-Maraghi RH, Hammel P, et al.nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.J Natl Cancer Inst 2015, 107.
11.Rougier P, Riess H, Manges R, et al.Randomised, placebocontrolled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving firstline treatment with gemcitabine for metastatic pancreatic cancer.Eur J Cancer 2013, 49: 2633-2642.(https://www.daowen.com)
12.Ioka T, Okusaka T, Ohkawa S, et al.Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.Jpn J Clin Oncol 2015, 45: 439-448.
13.Evans TR, Van Cutsem E, Moore MJ, et al.Phase 2 placebocontrolled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.Ann Oncol 2016.
14.Catenacci DV, Junttila MR, Karrison T, et al.Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer.J Clin Oncol 2015, 33: 4284-4292.
15.Lee HS, Chung MJ, Park JY, et al.A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.Medicine(Baltimore)2017, 96: e5702.
16.Li Y, Sun J, Jiang Z, et al.Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.J Chemother 2015, 27: 227-234.
17.Yamaue H, Shimizu A, Hagiwara Y, et al.Multicenter, randomized, open-label phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer.Cancer Chemother Pharmacol 2017, 79: 813-823.
18.Suker M, Beumer BR, Sadot E, et al.FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.Lancet Oncol 2016, 17: 801-810.
19.Stein SM, James ES, Deng Y, et al.Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.Br J Cancer 2016, 114: 809-812.
20.Chung V, McDonough S, Philip PA, et al.Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial.JAMA Oncol 2017, 3: 516-522.
21.Rosati LM, Herman JM.Role of stereotactic body radiotherapy in the treatment of elderly and poor performance status patients with pancreatic cancer.J Oncol Pract 2017, 13: 157-166.